Endocrine Abstracts

Objective: To study the characteristics of a cohort of patients with Graves’ orbitopathy (GO) as a self-audit prior to the creation of a multidisciplinary team for the global approach of these patients.

Material and Methods: Retrospective study of patients with GO treated at the Endocrinology and Ophthalmology Services of a tertiary referral hospital (Virgen Macarena University Hospital, Seville, Andalusia, Spain) between 2018 and 2021. The following variables were evaluated in a cohort of 267 patients: demographic data; date and service of diagnosis; number of visits; thyroid function at diagnosis of GO; highest severity of GO and highest level of anti-TRAb (TSI) reached during follow-up; imaging; treatments for GO and EG; smoking.

Results: The results of the 267 analyzed patients are described in Table 1. The severity of the GO was analyzed according to the EUGOGO classification: 56.93% had mild GO, 41.57% moderate to severe, and 1.50% with visual risk. Highest level of anti-TRAb (TSI) reached during follow-up was recorded in 237 patients of the total, with a mean of 15.93 IU/l ± 13.49 IU/l SD. Regarding the treatment of GD, 89.98% of the patients were treated with antithyroid drugs, 15.36% received radioactive iodine (the majority without corticosteroid prophylaxis) and 40.82% required total thyroidectomy. With regard to smoking, 41.57% were active smokers, with 81% being offered anti-smoking advice and referring 14.4% of all smokers to the Smoking Cessation Unit of the Pneumology Service.

Conclusions: After analyzing our cohort of patients with GO, we have detected some areas for improvement: A corticosteroid prophylaxis deficit has been observed in the context of radioactive iodine administration for the treatment of GD. Referral to the Smoking Cessation Unit should be performed routinely in all smokers with GD. The analysis of these results will allow us to optimize the multidisciplinary management of our patients with GO.